AU2016256582B2 - Oncolytic adenovirus encoding a B7 protein - Google Patents

Oncolytic adenovirus encoding a B7 protein Download PDF

Info

Publication number
AU2016256582B2
AU2016256582B2 AU2016256582A AU2016256582A AU2016256582B2 AU 2016256582 B2 AU2016256582 B2 AU 2016256582B2 AU 2016256582 A AU2016256582 A AU 2016256582A AU 2016256582 A AU2016256582 A AU 2016256582A AU 2016256582 B2 AU2016256582 B2 AU 2016256582B2
Authority
AU
Australia
Prior art keywords
cells
virus
protein
sequence
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016256582A
Other languages
English (en)
Other versions
AU2016256582A8 (en
AU2016256582A1 (en
Inventor
Alice Claire Noel BROMLEY
Brian Robert Champion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akamis Bio Ltd
Original Assignee
Akamis Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1507419.8A external-priority patent/GB201507419D0/en
Priority claimed from GBGB1516936.0A external-priority patent/GB201516936D0/en
Priority claimed from GBGB1522013.0A external-priority patent/GB201522013D0/en
Application filed by Akamis Bio Ltd filed Critical Akamis Bio Ltd
Publication of AU2016256582A1 publication Critical patent/AU2016256582A1/en
Publication of AU2016256582A8 publication Critical patent/AU2016256582A8/en
Priority to AU2018201446A priority Critical patent/AU2018201446B2/en
Priority to AU2020223665A priority patent/AU2020223665A1/en
Publication of AU2016256582B2 publication Critical patent/AU2016256582B2/en
Application granted granted Critical
Assigned to Akamis Bio Limited reassignment Akamis Bio Limited Request to Amend Deed and Register Assignors: PSIOXUS THERAPEUTICS LIMITED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2016256582A 2015-04-30 2016-04-29 Oncolytic adenovirus encoding a B7 protein Active AU2016256582B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018201446A AU2018201446B2 (en) 2015-04-30 2018-02-28 Oncolytic adenovirus encoding a B7 protein
AU2020223665A AU2020223665A1 (en) 2015-04-30 2020-08-25 Oncolytic adenovirus encoding a B7 protein

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1507419.8A GB201507419D0 (en) 2015-04-30 2015-04-30 Virus
GB1507419.8 2015-04-30
GBGB1516936.0A GB201516936D0 (en) 2015-09-24 2015-09-24 Virus
GB1516936.0 2015-09-24
GBGB1522013.0A GB201522013D0 (en) 2015-12-14 2015-12-14 Virus
GB1522013.0 2015-12-14
PCT/EP2016/059609 WO2016174200A1 (en) 2015-04-30 2016-04-29 Oncolytic adenovirus encoding a b7 protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018201446A Division AU2018201446B2 (en) 2015-04-30 2018-02-28 Oncolytic adenovirus encoding a B7 protein

Publications (3)

Publication Number Publication Date
AU2016256582A1 AU2016256582A1 (en) 2017-11-16
AU2016256582A8 AU2016256582A8 (en) 2018-01-18
AU2016256582B2 true AU2016256582B2 (en) 2020-10-29

Family

ID=56008588

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016256582A Active AU2016256582B2 (en) 2015-04-30 2016-04-29 Oncolytic adenovirus encoding a B7 protein
AU2018201446A Active AU2018201446B2 (en) 2015-04-30 2018-02-28 Oncolytic adenovirus encoding a B7 protein
AU2020223665A Abandoned AU2020223665A1 (en) 2015-04-30 2020-08-25 Oncolytic adenovirus encoding a B7 protein

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018201446A Active AU2018201446B2 (en) 2015-04-30 2018-02-28 Oncolytic adenovirus encoding a B7 protein
AU2020223665A Abandoned AU2020223665A1 (en) 2015-04-30 2020-08-25 Oncolytic adenovirus encoding a B7 protein

Country Status (31)

Country Link
US (6) US11000559B2 (enExample)
EP (2) EP3391892A1 (enExample)
JP (3) JP6931229B2 (enExample)
KR (4) KR102643574B1 (enExample)
CN (2) CN107690479B (enExample)
AU (3) AU2016256582B2 (enExample)
BR (2) BR122018004815A2 (enExample)
CA (1) CA2984038C (enExample)
CL (2) CL2017002731A1 (enExample)
CO (1) CO2017010831A2 (enExample)
CY (1) CY1122833T1 (enExample)
DK (1) DK3288573T3 (enExample)
EA (1) EA037611B1 (enExample)
ES (1) ES2780366T3 (enExample)
HR (1) HRP20200439T1 (enExample)
HU (1) HUE048320T2 (enExample)
IL (3) IL284375B (enExample)
LT (1) LT3288573T (enExample)
MX (1) MX2017013684A (enExample)
MY (1) MY183703A (enExample)
PE (2) PE20181140A1 (enExample)
PH (1) PH12017501942A1 (enExample)
PL (1) PL3288573T3 (enExample)
PT (1) PT3288573T (enExample)
RS (1) RS60105B1 (enExample)
SA (2) SA520412637B1 (enExample)
SG (3) SG10201803081TA (enExample)
SI (1) SI3288573T1 (enExample)
SM (1) SMT202000222T1 (enExample)
WO (1) WO2016174200A1 (enExample)
ZA (1) ZA201801589B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3007711B1 (en) 2013-06-14 2020-10-21 Psioxus Therapeutics Limited A dosing regime and formulations for type b adenoviruses
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
TR201802728T4 (tr) 2013-10-25 2018-03-21 Psioxus Therapeutics Ltd Heterolog genlerle donatılmış onkolitik adenovirüsler.
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
BR122018004815A2 (pt) 2015-04-30 2019-09-10 Psioxus Therapeutics Ltd adenovírus oncolítico que codifica proteína b7
MA43163A (fr) 2015-11-02 2018-09-12 Five Prime Therapeutics Inc Polypeptides à domaine extracellulaire cd80 et leur utilisation dans le traitement du cancer
EA201891022A1 (ru) * 2015-12-17 2019-01-31 Псайоксус Терапьютикс Лимитед Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
CN117534735A (zh) * 2016-03-31 2024-02-09 欧洲分子生物学实验室 腺病毒外壳蛋白衍生递送载体
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
CN119614520A (zh) 2016-08-29 2025-03-14 阿卡米斯生物公司 携带双特异性t细胞衔接器的腺病毒
CN117298260A (zh) * 2016-09-02 2023-12-29 莱蒂恩技术公司 用DuoCAR治疗癌症的组合物和方法
AU2017335673B2 (en) * 2016-09-27 2024-11-14 Sator Therapeutics LLC Optimized oncolytic viruses and uses thereof
WO2018083258A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083257A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083259A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
KR20190128050A (ko) 2017-02-03 2019-11-14 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 종양용해성 바이러스 요법
JP2020517913A (ja) 2017-04-28 2020-06-18 ファイブ プライム セラピューティクス， インコーポレイテッド Ｃｄ８０細胞外ドメインポリペプチドによる治療方法
KR20240132124A (ko) * 2017-05-25 2024-09-02 유니버시티 오브 센트럴 플로리다 리서치 파운데이션, 인코포레이티드 천연 살해 세포에 의해 사멸하는 종양 세포를 감작시키기 위한 신규한 종양용해 바이러스
CN120796389A (zh) 2017-05-26 2025-10-17 埃皮森特Rx股份有限公司 携带转基因的重组腺病毒
WO2018220207A1 (en) 2017-06-01 2018-12-06 Psioxus Therapeutics Limited Oncolytic virus and method
WO2019147921A1 (en) * 2018-01-26 2019-08-01 Nantcell, Inc. Rapid verification of virus particle production for a personalized vaccine
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
US12404312B2 (en) 2018-03-05 2025-09-02 Massachusetts Eye And Ear Infirmary Engineered VEGF variants for retinal neuroprotection, promotion of axon growth and axon regeneration
EP3789489A4 (en) * 2018-03-30 2022-01-05 Tomoki Todo ANTI-SWEEPER TYPE ONCOLYTIC VIRUS
CN119955743A (zh) * 2018-09-10 2025-05-09 上海锦斯生物技术有限公司 修饰的溶瘤病毒、其组合物和用途
KR20210135532A (ko) * 2019-03-05 2021-11-15 암젠 인크 암 치료를 위한 종양 용해 바이러스의 용도
EP3725323A1 (en) * 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada
KR102503349B1 (ko) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
US20220249127A1 (en) * 2019-05-14 2022-08-11 Oncolys Biopharma Inc. Method for administering oncolytic virus to tumor tissue, and device for administration
GB201909081D0 (en) 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
GB202102049D0 (en) * 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
CN113544263B (zh) * 2021-06-03 2022-12-06 上海允英生物医药科技有限公司 溶瘤病毒载体及其应用
EP4404947A4 (en) 2021-09-23 2025-12-10 Sagittarius Bio Inc Adenovirus and Methods of Using Adenovirus
EP4499846A1 (en) * 2022-03-25 2025-02-05 Universität Zürich Adenoviral mediated targeting of activated immune cells
AU2024277678A1 (en) 2023-05-25 2025-11-27 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003064666A1 (en) * 2002-02-01 2003-08-07 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
US20050175589A1 (en) * 2001-07-13 2005-08-11 Btg International Limited Anti-neoplastic viral agents
AU2010244348A1 (en) * 2009-05-06 2011-12-01 Fundacio Privada Institut D'investigacio Biomedica De Bellvitge Oncolytic adenoviruses for treating cancer
WO2015155370A1 (en) * 2014-04-12 2015-10-15 Psioxus Therapeutics Limited Group b adenovirus modified in the e4orf4 region

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
ES2310924T3 (es) 1993-07-13 2009-01-16 Centelion Vectores adenovirales defectivos y utilizacion en terapia genica.
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
CN1242051A (zh) 1996-12-31 2000-01-19 昂尼克斯药物公司 用于肿瘤治疗和预防的致细胞病变病毒
DE69838510T2 (de) 1997-02-20 2008-07-03 Johns Hopkins University School Of Medicine Mutationen in atp-abhängigen transpositionsproteinen die die zielortspezifität reduzieren
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US20020019051A1 (en) 1998-05-27 2002-02-14 Monika Lusky Chimeric adenoviral vectors
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CN1110553C (zh) 1998-07-15 2003-06-04 杭州赛狮生物技术开发有限公司 基因工程腺病毒及其用途
CA2342396A1 (en) * 1998-09-11 2000-03-23 Genvec, Inc. Alternatively targeted adenovirus
EP1137792B9 (en) 1998-12-09 2007-12-12 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services A recombinant vector expressing multiple costimulatory molecules and uses thereof
EP1816204B1 (en) 1999-05-17 2010-10-20 Crucell Holland B.V. Recombinant Adenovirus of the Ad26 serotype
EP1181382B1 (en) 1999-06-01 2005-03-23 The University of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
US7396679B2 (en) 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
KR100802403B1 (ko) * 2000-01-21 2008-02-13 바이오벡스 리미티드 바이러스 주
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
EP1301612A2 (en) 2000-05-31 2003-04-16 Genvec, Inc. Method and composition for targeting an adenoviral vector
EP1348030B1 (en) 2001-01-04 2009-11-25 Wadell, Göran Viral vector for gene therapy
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
US7858367B2 (en) 2002-04-30 2010-12-28 Duke University Viral vectors and methods for producing and using the same
CN1705740B (zh) * 2002-10-15 2013-07-24 佩尔·松内·霍尔姆 具有反向基因表达的腺病毒及其应用
US20040167088A1 (en) 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
US20040213764A1 (en) 2003-03-28 2004-10-28 William Wold Adenovirus replication-competent vectors expressing trail
US20050136035A1 (en) 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
CA2527369A1 (en) 2003-07-18 2005-02-03 Onyx Pharmaceuticals, Inc. Subgroup b adenoviral vectors for treating disease
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
WO2005086922A2 (en) 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
WO2005107474A2 (en) 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
WO2005118825A2 (en) 2004-05-26 2005-12-15 Schering Aktiengesellschaft Chimeric adenoviruses for use in cancer treatment
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
US20060292682A1 (en) * 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
CN101068933A (zh) * 2004-08-25 2007-11-07 细胞基因系统有限公司 用于肿瘤细胞增强转导的纤维修饰的腺病毒载体
WO2006039045A2 (en) * 2004-09-01 2006-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
EP1819823A2 (en) 2004-12-01 2007-08-22 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
WO2007027860A2 (en) 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
DE102005055128B4 (de) 2005-11-15 2015-04-02 Universität Rostock Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
ES2304281B1 (es) 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
WO2008080003A2 (en) 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Generation of oncolytic adenoviruses and uses thereof
MX339014B (es) 2008-05-27 2016-05-09 Oncolytics Biotech Inc Modulacion de presion intersticial y suministro y distribucion viral oncolitica.
CN101381742A (zh) * 2008-10-23 2009-03-11 浙江理工大学 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用
WO2011043719A1 (en) * 2009-10-05 2011-04-14 Ya-Fang Mei Replicating viral vectors for gene therapy
EP2606127B1 (en) 2010-08-16 2019-03-20 Salk Institute For Biological Studies Adenoviral assembly method
EP2619312A1 (en) 2010-09-24 2013-07-31 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies
EP2619224A1 (en) * 2010-09-24 2013-07-31 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
JP2015507604A (ja) 2011-11-14 2015-03-12 リジェネレイティブ サイエンシーズ， エルエルシー 懸濁粒子送達システムおよび方法
CN102586327B (zh) 2012-01-18 2013-09-11 陕西师范大学 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用
WO2014138314A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
TR201802728T4 (tr) * 2013-10-25 2018-03-21 Psioxus Therapeutics Ltd Heterolog genlerle donatılmış onkolitik adenovirüsler.
CA2931322A1 (en) 2013-11-22 2015-05-28 Dnatrix, Inc. Adenovirus expressing immune cell stimulatory receptor agonist(s)
GB201510197D0 (en) * 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
GB201503500D0 (en) 2015-03-02 2015-04-15 Ucl Business Plc Cell
CN107406859A (zh) 2015-03-17 2017-11-28 倾斜生物医疗公司 编码双特异性抗体的溶瘤腺病毒及与其相关的方法和用途
BR122018004815A2 (pt) 2015-04-30 2019-09-10 Psioxus Therapeutics Ltd adenovírus oncolítico que codifica proteína b7
EA201891022A1 (ru) 2015-12-17 2019-01-31 Псайоксус Терапьютикс Лимитед Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
JP2019508044A (ja) 2016-03-18 2019-03-28 ナントセル，インコーポレイテッド 樹状細胞感染のための多モードベクター
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
CN119614520A (zh) 2016-08-29 2025-03-14 阿卡米斯生物公司 携带双特异性t细胞衔接器的腺病毒
AU2017345764A1 (en) 2016-10-20 2019-05-02 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083259A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018220207A1 (en) * 2017-06-01 2018-12-06 Psioxus Therapeutics Limited Oncolytic virus and method
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050175589A1 (en) * 2001-07-13 2005-08-11 Btg International Limited Anti-neoplastic viral agents
WO2003064666A1 (en) * 2002-02-01 2003-08-07 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
AU2010244348A1 (en) * 2009-05-06 2011-12-01 Fundacio Privada Institut D'investigacio Biomedica De Bellvitge Oncolytic adenoviruses for treating cancer
WO2015155370A1 (en) * 2014-04-12 2015-10-15 Psioxus Therapeutics Limited Group b adenovirus modified in the e4orf4 region

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHOI K-J ET AL, "Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect", GENE THERAPY, vol. 13, no. 13, doi:10.1038/SJ.GT.3302759, ISSN 0969-7128, (2006-07-01), pages 1010 - 1020, (2006-03-09) *
JIN F ET AL: MOLECULAR THERAPY, vol 12, no. 6, 13 September 2005 (online), pages 1052-1063, DOI: https://doi.org/10.1016/j.ymthe.2005.07.696 *
LEE Y-S ET AL, "Enhanced Antitumor Effect of Oncolytic Adenovirus Expressing Interleukin-12 and B7-1 in an Immunocompetent Murine Model", CLIN CANCER RES (2006 Oct 1) vol. 12, no. 19, pp 5859-5868, doi:10.1158/1078-0432.CCR-06-0935 *
PAUL S ET AL, "The combination of a chemokine, cytokine and TCR-based T cell stimulus for effective gene therapy of cancer", CANCER IMMUNOL IMMUNOTHER (2002 Dec) vol. 51, no. 11-12, pp 645-654, https://doi.org/10.1007/s00262-002-0314-2 *
Z-B HU ET AL, "A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes", CANCER GENE THERAPY, (2008-03-01), vol. 15, no. 3, doi:10.1038/sj.cgt.7701105, ISSN 0929-1903, pages 173 - 182 *

Also Published As

Publication number Publication date
CN108396015B (zh) 2022-02-18
CA2984038A1 (en) 2016-11-03
PT3288573T (pt) 2020-03-25
US11000559B2 (en) 2021-05-11
BR112017023171A2 (pt) 2018-07-17
MX2017013684A (es) 2018-08-28
SG10201803081TA (en) 2018-06-28
IL284375A (en) 2021-07-29
ES2780366T3 (es) 2020-08-25
EA201791971A1 (ru) 2018-04-30
IL255286B (en) 2021-01-31
SG11201708604TA (en) 2017-11-29
LT3288573T (lt) 2020-03-25
JP2018139586A (ja) 2018-09-13
AU2016256582A8 (en) 2018-01-18
US10124028B2 (en) 2018-11-13
BR122018004815A2 (pt) 2019-09-10
US20180140649A1 (en) 2018-05-24
US10322152B2 (en) 2019-06-18
KR102643574B1 (ko) 2024-03-06
SA517390260B1 (ar) 2021-11-10
SA520412637B1 (ar) 2022-03-01
KR20240032177A (ko) 2024-03-08
PH12017501942A1 (en) 2018-03-19
CO2017010831A2 (es) 2018-02-28
JP2021176339A (ja) 2021-11-11
EP3288573A1 (en) 2018-03-07
JP6928380B2 (ja) 2021-09-01
EP3391892A1 (en) 2018-10-24
PL3288573T3 (pl) 2020-05-18
PE20180241A1 (es) 2018-01-31
WO2016174200A1 (en) 2016-11-03
CL2018000587A1 (es) 2018-08-10
SG10201901482XA (en) 2019-03-28
HRP20200439T1 (hr) 2020-06-12
KR20180022638A (ko) 2018-03-06
HUE048320T2 (hu) 2020-07-28
AU2016256582A1 (en) 2017-11-16
ZA201801589B (en) 2019-10-30
IL255286A0 (en) 2017-12-31
CN107690479A (zh) 2018-02-13
SMT202000222T1 (it) 2020-05-08
KR20250134212A (ko) 2025-09-09
US10849945B2 (en) 2020-12-01
DK3288573T3 (da) 2020-03-16
JP7162929B2 (ja) 2022-10-31
EP3288573B1 (en) 2020-02-12
CN107690479B (zh) 2022-02-18
KR20180118249A (ko) 2018-10-30
CY1122833T1 (el) 2021-05-05
JP2018514199A (ja) 2018-06-07
CL2017002731A1 (es) 2018-06-08
JP6931229B2 (ja) 2021-09-01
US20190076493A1 (en) 2019-03-14
IL258044A (en) 2018-05-31
US20210338753A1 (en) 2021-11-04
SI3288573T1 (sl) 2020-06-30
CN108396015A (zh) 2018-08-14
IL258044B (en) 2021-07-29
AU2020223665A1 (en) 2020-09-10
AU2018201446B2 (en) 2020-05-28
AU2018201446A1 (en) 2018-03-29
EA037611B1 (ru) 2021-04-21
KR102854512B1 (ko) 2025-09-04
US20170056458A1 (en) 2017-03-02
MY183703A (en) 2021-03-09
US20180042973A1 (en) 2018-02-15
PE20181140A1 (es) 2018-07-17
CA2984038C (en) 2023-01-03
RS60105B1 (sr) 2020-05-29
US20170266243A1 (en) 2017-09-21
HK1249009A1 (en) 2018-10-26
IL284375B (en) 2022-07-01
US10548929B2 (en) 2020-02-04

Similar Documents

Publication Publication Date Title
AU2016256582B2 (en) Oncolytic adenovirus encoding a B7 protein
KR102857666B1 (ko) 항-tcr-복합체 항체 또는 단편을 암호화하는 군 b 아데노바이러스
WO2018083258A1 (en) Oncolytic adenovirus encoding at least three transgenes
WO2018083257A1 (en) Oncolytic adenovirus encoding transgenes
HK1263149A1 (en) Oncolytic adenovirus encoding a b7 protein
HK1249009B (en) Oncolytic adenovirus encoding a b7 protein

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 31 , NO 45 , PAGE(S) 6561 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME PSIOXUS THERAPEUTICS LIMITED, APPLICATION NO. 2016256582, UNDER INID (72) CORRECT THE CO-INVENTOR TO BROMLEY, ALICE CLAIRE NOEL

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: AKAMIS BIO LIMITED

Free format text: FORMER NAME(S): PSIOXUS THERAPEUTICS LIMITED